What are the precautions for ramucirumab (ramucirumab)?

Ramucirumab (ramucirumab) is a type of drug called a monoclonal antibody, which works by stopping the growth of cancer cells. When stomach cancer or cancer located at the junction of the stomach and esophagus (the tube between the throat and stomach) does not improve after treatment with other drugs, ramucirumab injection may be used alone or in combination with another chemotherapy drug to treat these conditions. Ramucirumab is also used in combination with docetaxel to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is not improving or getting worse in people treated with other chemotherapy drugs. It is also used in combination with erlotinib (Tarceva) to treat a certain type of non-small cell lung cancer that has spread to other parts of the body. Ramucirumab is also used in combination with other chemotherapy drugs to treat cancer of the colon (large intestine) or rectum in people who have been treated with other chemotherapy drugs and have not improved or gotten worse. Ramucirumabis also used alone to treat certain patients with hepatocellular carcinoma (HCC; a type of liver cancer) who have been treated with sorafenib (Nexafar ).

Bleeding: Ramucirumab may increase the risk of bleeding and gastrointestinal bleeding, including serious and fatal events. Ramucirumab should be permanently discontinued in patients who develop severe bleeding.

Gastrointestinal perforation: Ramucirumab increases the risk of gastrointestinal perforation, which may be fatal. Ramucirumab should be permanently discontinued in patients who develop gastrointestinal perforation.

Impaired wound healing:Discontinue silamza 28 days before elective surgery. Do not take ramucirumab for at least 2 weeks after major surgery and until the wound is completely healed. The safety of resuming ramucirumab after resolution of wound healing complications has not been established.

Arterial Thromboembolic Events: Serious and sometimes fatal acute respiratory tract infections may occur with ramucirumab. Patients with ATE should permanently discontinue ramucirumab.

Hypertension:Monitor blood pressure and treat high blood pressure. Discontinue ramucirumab in patients with severe hypertension. Ramucirumab should be permanently discontinued in patients with hypertension uncontrolled by antihypertensive therapy and in hypertensive crisis or hypertensive encephalopathy.

Infusion-related reactions (IRR):Monitor for signs and symptoms during infusion. Reduce the infusion rate of Grade 1 or Grade 2IRR and Permanently discontinue the infusion rate of Grade or Grade Grade IRR.

Exacerbation of existing liver damage: Patients with Child-Pugh B or C cirrhosis may develop new or worsening encephalopathy, ascites, or hepatorenal syndrome.

Posterior reversible encephalopathy syndrome: Permanently discontinued Ramucirumab .

Proteinuria includes nephrotic syndrome:Monitor for proteinuria. Ramucirumab should be discontinued in patients with urine protein levels greater than or equal to 2 g/span>per 24 hours. Permanently discontinue ramucirumab if urine protein levels exceed 3 grams per 24 hours or if nephrotic syndrome occurs.

Thyroid Dysfunction:Monitor thyroid function during treatment.

Embryo-Fetal Toxicity:Can cause fetal harm. Inform women of reproductive potential of potential risks to the fetus and use effective contraceptive measures.

Ramucirumab This drug is available in Hong Kong, and the retail price in Hong Kong pharmacies is about 500mg3 around 10,000. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.